DCLK1 and intestinal neoplasm: To test the therapeutic effect of DCLK1-IN-1, we inoculated murine intestinal tumor cells (MC-38) into a syngeneic mouse model that is applicable for monitoring PGE2-induced microenvironmental changes, including changes in inflammation and immune responses.